LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bacterial Composition Linked to Breast Cancer

By LabMedica International staff writers
Posted on 19 Oct 2017
Print article
Image: The Quantiflour dsDNA system for sensitive quantitation of double-stranded DNA in solution (Photo courtesy of Promega).
Image: The Quantiflour dsDNA system for sensitive quantitation of double-stranded DNA in solution (Photo courtesy of Promega).
Breast cancer is the second most common cancer in women (after skin cancer) in the USA, where one in eight women will develop the disease in their lifetimes. Bacteria that live in the body is known as the microbiome, and influence many diseases.

Most studies have been done on the "gut" microbiome, or bacteria in the digestive tract. Scientists have long suspected that a "microbiome" exists within breast tissue and plays a role in breast cancer, but it has not yet been characterized. Recently they have uncovered differences in the bacterial composition of breast tissue of healthy women versus women with breast cancer.

Scientists at the Cleveland Clinic (Cleveland, OH, USA) examined the tissues of 78 patients who underwent mastectomy for invasive carcinoma or elective cosmetic breast surgery. In addition, they examined oral rinse and urine to determine the bacterial composition of these distant sites in the body. Breast cancer patients eligible for inclusion for this study were over 18 years of age, female, had tumors greater than or equal to 2 cm in size, and were undergoing mastectomy.

The team extracted total DNA was from the breast tissue, environmental controls, urine, and oral rinse pellets using PowerMag Microbiome RNA/DNA Isolation Kit. For breast samples, the polymerase chain reaction (PCR) product showed nonspecific bands on a 1% agarose gel. A second round of Ampure XP cleanup was performed and resulting libraries were quantified with Quantiflour dsDNA system. Libraries were validated on a Bioanalyzer DNA 1000 chip to verify size and sequenced.

The scientists found that cancer patient breast tissue microbiomes clustered significantly differently from non-cancer patients, largely driven by decreased relative abundance of Methylobacterium in cancer patients (median 0.10 versus 0.24). There were no significant differences in oral rinse samples. Differences in urinary microbiomes were largely explained by menopausal status, with peri/postmenopausal women showing decreased levels of Lactobacillus. Independent of menopausal status, however, cancer patients had increased levels of gram-positive organisms including Corynebacterium, Staphylococcus, Actinomyces, and Propionibacteriaceae.

Charis Eng, MD, PhD, the co-senior author of the study, said, “To my knowledge, this is the first study to examine both breast tissue and distant sites of the body for bacterial differences in breast cancer. Our hope is to find a biomarker that would help us diagnose breast cancer quickly and easily. In our wildest dreams, we hope we can use microbiomics right before breast cancer forms and then prevent cancer with probiotics or antibiotics.” The study was published on October 5, 2017, in the journal Oncotarget.

Related Links:
Cleveland Clinic

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.